Trial Profile
Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Conjugated estrogens/bazedoxifene (Primary)
- Indications Major depressive disorder; Perimenopause
- Focus Pharmacodynamics
- 01 Feb 2022 Status changed from recruiting to completed.
- 06 Dec 2021 Status changed from suspended to recruiting.
- 09 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.